VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim

• Main Authors: Mustafa, N, Ting Lee, J.X, Adina Nee, H.F, Bi, C, Chung, T.-H, Hart, S, Chng, W.J
• Other Authors: MEDICINE
• Format: Article
• Published: 2020
• Subjects: 5 (9 isopropyl 8 methyl 2 morpholino 9h purin 6 yl) 2 pyrimidinamine; beta catenin; BIM protein; bortezomib; caspase 3; cyclin D2; cyclin dependent kinase 4; cytochrome c; dexamethasone; dickkopf 1 protein; mammalian target of rapamycin; melphalan; messenger RNA; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase; panobinostat; phosphatidylinositol 3 kinase; protein Bax; protein bcl xl; protein kinase B; protein S6; survivin; Akt signaling; animal experiment; animal model; antineoplastic activity; apoptosis; Article; cancer inhibition; cell viability; cellular distribution; concentration response; controlled study; cytosol; down regulation; drug cytotoxicity; drug effect; drug efficacy; drug mechanism; drug potentiation; enzyme activation; enzyme activity; female; G1 phase cell cycle checkpoint; gene expression profiling; gene expression regulation; gene silencing; human; human cell; IC50; in vivo study; mouse; multiple myeloma; multiple myeloma cell line; nonhuman; protein cleavage; protein expression; protein phosphorylation; RARRES3 gene; therapeutic index; tumor suppressor gene; tumor volume; tumor xenograft; upregulation
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/173800
• Institution: National University of Singapore

10.18632/oncotarget.21988